ClinicalTrials.gg
RecruitingNCT03230565Updated Dec 8, 2025

Continuous Infusions vs Scheduled Bolus Infusions

A Phase 4 interventional study of Ropivacaine and Ropivacaine in Surgical Procedure, Unspecified and Pain, Postoperative, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Stanford University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2018; still recruiting 8 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
5th of 184
240 · median 70
Started
2018
with 11 others
Phase 4
84 of 184
7 open now
Primary completion
2026-12
later than 14 of 21 live
Registered
96th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 5th largest by planned enrollment, is one of 12 that started in 2018, is one of 84 in phase 4, reaches primary completion later than 14 of the 21 other live ones, and was the 96th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of the study is to compare continuous infusions and scheduled bolus infusions for peripheral nerve blocks and their effect on post-surgical pain.

Read the detailed description

Regional anesthetic techniques are an integral part to many anesthetic approaches, providing both intraoperative and postoperative anesthesia and analgesia. Regional anesthesia peripheral nerve blocks have been shown to reduce postoperative pain and improve measures such as opioid requirements and readiness for discharge. By using a catheter technique for continuous peripheral nerve blocks, analgesia can be extended well into post-operative days 2 and 3, further extending these benefits. Historically these catheters have implemented a continuous dosing regimen of local anesthetic, but increasingly there is evidence of improved analgesic outcomes without adverse effects by using a scheduled bolus dosing regimen. Many institutions have implemented this new protocol for catheter dosing. The beneficial effect of scheduled bolus dosing has not been studied in all blocks and all surgical procedures.

The study will consist of three independent arms, each designed to evaluate a different nerve block site: interscalene, adductor canal, and infraclavicular. A total of 60 patients will be enrolled in each arm.

03

Conditions studied

  • Surgical Procedure, Unspecified
  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients presenting for nerve block catheters for post-operative analgesia
  • I, II, or III.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Incarceration
  • Age \<18
  • >35
  • Pre-operative opioid use >30 mg morphine equivalents per day
  • Inability to communicate with investigators by telephone
  • Pre-existing neuropathy of the operative extremity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Continuous Infusion

    Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.

    Drug: Ropivacaine

  • Active comparator
    Intermittent Bolus Infusion

    Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.

    Drug: Ropivacaine

Interventions

  • Patient will be given a continuous infusion of local anesthetic.

    Also known as: Continuous infusion

  • Patient will be given a scheduled intermittent bolus of local anesthetic.

    Also known as: Bolus Infusion

06

What researchers measure

Primary outcomes

  1. Post-surgical pain

    Pain scores will be collected using a Numeric Rating Scale (NRS) from 0-10, where 0 is the lowest and 10 is the highest pain level.

    Time frame: Post-operative day 0, 1, and 2

Secondary outcomes

  1. Opioid consumption

    The amount of opioid analgesics (converted to total morphine milligram equivalents) taken by patients will be recorded.

    Time frame: Post-operative day 0, 1, and 2

  2. Local anesthetic use

    The amount of supplemental local anesthetic boluses self-administered by patients will be recorded (in mL).

    Time frame: Post-operative day 1 and 2

  3. Quality of recovery

    Quality of recovery will be assessed using a Quality of Recovery (QoR-15) questionnaire. The QoR15 scores range from 0 to 150, where 0 is poor recovery and 150 is excellent recovery.

    Time frame: Post-operative day 1 and 2

  4. Evidence of diaphragmatic paralysis

    Ability to breathe will be assessed as a part of QoR-15 questionnaire on 11-point scale, where 0 is never being able to breathe easily and 10 is always being able to breathe easily.

    Time frame: Post-operative day 1 and 2

  5. Patient satisfaction

    Patients will be asked to assess their satisfaction with pain management (Yes/No).

    Time frame: Post-operative day 1 and 2

07

Study locations

1 of 1 sites recruiting
  • Stanford University
    Stanford, California 94305, United States
    Recruiting
    • Archana Verma · Contact
    • Jean Louis-Horn, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Dec 2026, 102 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 102 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 26, 2017
StartActual
Jun 1, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03230565
Responsible party
Jean-Louis Horn (Professor of Anesthesiology, Stanford University) — Principal investigator
First posted
Jul 26, 2017
Start date
Jun 1, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 8, 2025

Study contacts

Aaron J Deng, BS
Contact
adeng1@stanford.edu
408-914-5494
Jean Louis-Horn, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion